BMS Korea keeps top spot in chronic hepatitis B market

Published: 2013-05-21 07:00:00

Updated: 2013-05-21 07:00:00

BMS Korea, a Korean unit of Bristol Myers Squibb Company, maintained its dominant position in the domestic chronic hepatitis B market during the January-April period of the year, although its competitor Gilead Sciences is slowly expanding market share, industry data showed recently.

According to the data compiled by Shinhan Investment & Securities, outpatient sales of Baraclude (entecavir), ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.